A Phase 2 interventional study of Chidamide and Venetoclax in Acute Myeloid Leukemia, sponsored by Guangdong Provincial People's Hospital. Recruiting at 13 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Guangdong Provincial People's Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing tucidinostat in Leukemia, Myeloid, Acute — 11 open to participants now, 11 under way, 1 of them phase 3. tucidinostat · Leukemia, Myeloid, Acute.
Among the 14 studies testing tucidinostat in Leukemia, Myeloid, Acute, this one has the largest planned enrollment, is one of 5 that started in 2024, is one of 9 in phase 2, reaches primary completion later than 2 of the 10 other live ones, and was the 9th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →11 of the 14 studies testing tucidinostat in Leukemia, Myeloid, Acute are open now, in 1 country. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–75
Chinese PLA General Hospital · Sites in China
Ages 60–75
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Chinese PLA General Hospital · Sites in China
Ages 14–75
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 1
First in 2021; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 99 across the 14 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 8 most frequent:
Guangdong Provincial People's Hospital is the lead sponsor of 237 studies on the registry; 102 are open to participants now.
Guangdong Provincial People's Hospital has 3 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
5 of the studies testing tucidinostat in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
| NCT06066905Guangdong Provincial People's HospitalA Study of Chidamide With AZA in MRD Positive AML After Transplant | 2026-12 |
| NCT06220162The First Affiliated Hospital of Soochow UniversityVAC Regimen for AML Patients Who Failed to Response to VA Regimen | 2026-12-01 |
| NCT06451861Guangdong Provincial People's HospitalRandomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | 2026-12-30 |
| NCT07304232Institute of Hematology & Blood Diseases Hospital, ChinaPost-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML | 2026-12-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 14 studies testing tucidinostat in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia
Acute myeloid leukemia (AML) is a clonal malignant blood disease with genetic heterogeneity and originated from hematopoietic stem progenitor cells.In the past 50 years, the "3+7" induction regimen represented by cytotoxic drugs (including anthracyclines/anthraquinones combined with cytarabine) has remained the standard induction regimen for newly diagnosed AML patients with intensive chemotherapy. In AML patients \<60 years old, the "3+7" regimen induces a complete response rate of 60% to 80%, but the treatment-related mortality is as high as 13%, and more than half of the patients face the threat of relapse, and the 5-year overall survival rate is about 35% to 40%.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZA,Venetoclax,Chidamide
Drug: Chidamide · Drug: Venetoclax · Drug: azacitidine
Daunorubicin/idarubicin/mitoxantrone and cytarabine
Drug: Anthracyclines or anthraquinones · Drug: cytarabine
AZA,Venetoclax
Drug: Venetoclax · Drug: azacitidine
Induction Therapy
Induction Therapy
Induction Therapy
Induction Therapy
Also known as: idarubicin, daunorubicin, mitoxantrone
Induction Therapy
Composite complete remission (CRc)
composite complete remission,CRc: CR + CRi + MLFS
Time frame: 2 months
the rate of MRD turn negative
minimal residual disease turn negative
Time frame: 6 months
DoR
Duration of remission
Time frame: 2 year
RFS
Relapsed-free survival
Time frame: 1 year
OS
Overall survival
Time frame: 1 year
AE
Incidence of of grade 3-4 adverse events/Duration of severe myelosuppression/ Incidence of severe infection/Treatment-related mortality, according to Common Terminology Criteria for Adverse Events, versions 5.0
Time frame: Throughout the study until the end, up to 2 years
Plan to share: No
Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 28 months is below that.
Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tucidinostat · Venetoclax · Azacitidine
Guangdong Provincial People's Hospital →